Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only Get Premium

Stock Analysis

EDIT Editas Medicine Inc

Price (delayed)

$1.51

Market cap

$126.41M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.04

Enterprise value

$73.43M

As a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a (also known as Cpf1) genome editing systems into a ...

Highlights

The debt has soared by 151% YoY but it has contracted by 7% from the previous quarter

The revenue has declined by 48% year-on-year but it has grown by 11% since the previous quarter

EDIT's equity has dropped by 79% year-on-year and by 54% since the previous quarter

Editas Medicine's net income has shrunk by 51% YoY and by 6% QoQ

Sector: Healthcare

Industry: Biotechnology

Website: http://www.editasmedicine.com

Peers: NVAX NVCR NBIX

Key stats

What are the main financial stats of EDIT

Market

Shares outstanding

83.71M

Market cap

$126.41M

Enterprise value

$73.43M

Valuations

Price to earnings (P/E)

N/A

Price to book (P/B)

2.01

Price to sales (P/S)

3.5

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

2.05

Earnings

Revenue

$35.84M

Gross profit

$35.84M

Operating income

-$260.33M

Net income

-$251.23M

EBIT

-$260.76M

EBITDA

-$254.44M

Free cash flow

-$215.28M

Per share

EPS

-$3.04

EPS diluted

-$3.04

Free cash flow per share

-$2.59

Book value per share

$0.75

Revenue per share

$0.43

TBVPS

$3.17

Balance sheet

Total assets

$263.65M

Total liabilities

$201.23M

Debt

$85.71M

Equity

$62.42M

Working capital

$151.73M

Liquidity

Debt to equity

1.37

Current ratio

3.08

Quick ratio

3.03

Net debt/EBITDA

0.21

Margins

EBITDA margin

-710%

Gross margin

100%

Net margin

-701.1%

Operating margin

-726.4%

Efficiency

Return on assets

-76.3%

Return on equity

-166.3%

Return on invested capital

-123.4%

Return on capital employed

-136.9%

Return on sales

-727.6%

Dividend

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

EDIT stock price

How has the Editas Medicine stock price performed over time

Intraday

8.24%

1 week

4.14%

1 month

18.9%

1 year

-74.36%

YTD

18.9%

QTD

30.17%

Financial performance

How have Editas Medicine's revenue and profit performed over time

Revenue

$35.84M

Gross profit

$35.84M

Operating income

-$260.33M

Net income

-$251.23M

Gross margin

100%

Net margin

-701.1%

The net margin has plunged by 193% YoY but it has grown by 4.4% from the previous quarter

EDIT's operating margin has dropped by 172% year-on-year but it is up by 7% since the previous quarter

Editas Medicine's net income has shrunk by 51% YoY and by 6% QoQ

The revenue has declined by 48% year-on-year but it has grown by 11% since the previous quarter

Price vs fundamentals

How does EDIT's price correlate with its fundamentals

Growth

What is Editas Medicine's growth rate over time

Valuation

What is Editas Medicine stock price valuation

P/E

N/A

P/B

2.01

P/S

3.5

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

2.05

EDIT's EPS is down by 46% year-on-year and by 6% since the previous quarter

EDIT's equity has dropped by 79% year-on-year and by 54% since the previous quarter

EDIT's P/B is 44% above its last 4 quarters average of 1.4 but 33% below its 5-year quarterly average of 3.0

The P/S is 89% less than the 5-year quarterly average of 31.5 and 15% less than the last 4 quarters average of 4.1

The revenue has declined by 48% year-on-year but it has grown by 11% since the previous quarter

Efficiency

How efficient is Editas Medicine business performance

EDIT's return on sales has dropped by 173% year-on-year but it is up by 6% since the previous quarter

EDIT's return on invested capital has dropped by 132% year-on-year and by 29% since the previous quarter

Editas Medicine's ROA has plunged by 128% YoY and by 20% from the previous quarter

The ROE has decreased by 47% from the previous quarter

Dividends

What is EDIT's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for EDIT.

Financial health

How did Editas Medicine financials performed over time

EDIT's total assets is 31% higher than its total liabilities

EDIT's total assets is down by 40% YoY and by 23% QoQ

EDIT's total liabilities is up by 38% year-on-year but it is down by 2.9% since the previous quarter

The debt is 37% more than the equity

The debt has soared by 151% YoY but it has contracted by 7% from the previous quarter

The company's debt to equity has surged by 99% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.